For academic and industrial laboratories investigating tissue protection and inflammatory signaling, rapid reagent delivery is critical to maintaining experimental timelines. PX1 Research provides high-purity ARA-290 with fast shipping directly from our US-based facilities in California and Arizona, ensuring lot-verified research compounds arrive quickly and securely for in vitro and animal models.
For academic and industrial laboratories investigating tissue protection and inflammatory signaling, rapid reagent delivery is critical to maintaining experimental timelines. PX1 Research provides high-purity ARA-290 with fast shipping directly from our US-based facilities in California and Arizona, ensuring lot-verified research compounds arrive quickly and securely for in vitro and animal models.
Sourcing high-purity ARA-290 with fast shipping requires a supplier operating robust domestic fulfillment hubs. PX1 Research dispatches all ARA-290 orders same-day when placed before cutoff times Monday through Friday, shipping directly from specialized distribution centers in California and Arizona to eliminate international customs delays and cross-border transit degradations.
Laboratory timelines rely on predictable supply chains. By maintaining immediate stock of research peptides manufactured under strict quality standards, PX1 Research allows investigator teams to maintain experimental momentum. Each shipment is packaged in temperature-managed, protective containers engineered to maintain peptide stability throughout transit, delivering verified research reagents ready for reconstitution.
ARA-290 (also known as cibinetide) is an 11-amino-acid synthetic peptide derived from the spatial structure of erythropoietin (EPO). Unlike native EPO, ARA-290 exhibits no binding affinity for the classical erythropoietin homodimer receptor ($EPOR_2$), meaning it does not stimulate erythropoiesis, hematocrit expansion, or reticulocyte production in research models.
Instead, ARA-290 selectively targets the Innate Repair Receptor (IRR), a heterocomplex comprising two erythropoietin receptor subunits and two common $\beta$ receptor subunits ($CD131$). In preclinical research, this structural selectivity enables researchers to evaluate non-hematopoietic tissue protection pathways without confounding hematological responses.
The primary mechanism of ARA-290 revolves around its specific agonism at the Innate Repair Receptor (IRR). The IRR is minimally expressed under basal physiological conditions but undergoes rapid upregulation in response to cellular stress, tissue injury, and local cytokine release. Detailed mechanical summaries are accessible in our comprehensive peptide research database.
Upon ligand binding to the $EPOR-CD131$ complex, ARA-290 initiates downstream anti-inflammatory and cytoprotective cascades. In vitro assays demonstrate that IRR activation inhibits p38 mitogen-activated protein kinase (MAPK) phosphorylation and suppresses nuclear factor kappa B (NF-$\kappa$B) nuclear translocation. This downregulates the transcription of pro-inflammatory mediators such as TNF-$\alpha$, IL-1$\beta$, and IL-6 while promoting anti-apoptotic signaling pathways.
Preclinical investigations using rodent models of metabolic, ischemic, and neuropathic distress demonstrate consistent tissue-protective effects following ARA-290 exposure. Animal studies focusing on small-fiber neuropathy models indicate that IRR signaling driven by ARA-290 mitigates microvascular inflammation and supports peripheral nerve fiber structural preservation.
In renal and cardiovascular ischemia-reperfusion models, preclinical data reveal that ARA-290 administration reduces apoptotic cell death within endothelial and parenchymal tissue. Researchers studying inflammatory signaling pathways note that the compound's targeted mechanism isolates local tissue repair responses from global systemic hematology, making it a valuable candidate for comparative signaling assays.
When designing protocols for tissue preservation and inflammatory pathway modulation, laboratories frequently compare ARA-290 against other prominent repair peptides in our research peptide catalog. While ARA-290 works exclusively via the heteromeric Innate Repair Receptor, compounds like BPC-157 target growth factor upregulation and nitric oxide pathways, and TB-500 acts via actin sequestration to influence cellular migration.
Additionally, tripeptides such as KPV function primarily through alpha-MSH receptor pathways to modulate localized inflammatory responses. ARA-290 is distinct in its origin as an EPO-derived helix-B surface peptide, offering researchers a uniquely specific probe for studying $EPOR-CD131$ heterodimer dynamics without cross-reacting with classical angiogenic or hematopoietic receptors.
To maintain the biochemical stability of ARA-290, strict handling protocols must be observed upon arrival. Lyophilized ARA-290 should be stored at $-20^\circ\text{C}$ for short-term evaluation or $-80^\circ\text{C}$ for long-term storage, shielded from light exposure. Avoid unnecessary freeze-thaw cycles, which can induce peptide aggregation and peptide bond cleavage.
Reconstitution should be conducted using sterile bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS, pH 7.4), depending on assay requirements. Gently swirl the vial until the lyophilized cake is fully dissolved; never vortex vigorously. Once reconstituted, stock solutions should be aliquoted into single-use microcentrifuge tubes and maintained at $-20^\circ\text{C}$ to preserve functional activity during trial series.
Assay reliability depends on high chemical purity and freedom from contaminants. PX1 ResearchSubjects every batch of ARA-290 to rigorous independent testing at an ISO 17025 accredited laboratory prior to release.
Our multi-step verification protocol includes Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to guarantee a purity profile exceeding 99%, Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular weight, and Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain strictly below $<0.5\text{ EU/mg}$. Lot-specific Certificates of Analysis (COAs) are publicly accessible for every sequence.
Academic institutions, CROs, and industrial research laboratories requiring high-volume reagents can leverage our streamlined logistics portal. Through our dedicated wholesale peptide ordering program, research facilities receive prioritized dispatch, dedicated account oversight, and custom lot reservation services.
Whether executing small-scale cell culture models or large-cohort animal trials, choosing PX1 Research ensures fast domestic shipping from California and Arizona, complete transparency, and fully verified analytical credentials for every lot of ARA-290.
What is the dispatch timeline for ARA-290 orders?
Orders placed before cutoff times Monday through Friday are processed and dispatched standard same-day from PX1 Research fulfillment facilities in California and Arizona.
What receptor does ARA-290 target in preclinical research?
ARA-290 is a selective agonist of the Innate Repair Receptor (IRR), which is a heterocomplex composed of erythropoietin receptor (EPOR) subunits and common beta receptor (CD131) subunits.
Does ARA-290 affect red blood cell counts in animal models?
No. Preclinical literature confirms that ARA-290 does not bind to the classical EPOR homodimer, meaning it does not stimulate erythropoiesis or alter hematocrit levels.
How is the purity of PX1 ARA-290 verified?
Every lot undergoes independent ISO 17025 third-party testing, including RP-HPLC for purity (>99%), ESI-MS for molecular mass verification, and LAL assays for endotoxin quantification.
What reconstitution solvent is recommended for ARA-290 in laboratory settings?
ARA-290 is typically reconstituted using sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4), depending on the requirements of the in vitro or in vivo model.
How should reconstituted ARA-290 be stored?
Reconstituted ARA-290 should be divided into single-use laboratory aliquots and stored at -20°C or -80°C to prevent degradation from repeated freeze-thaw cycles.
Can institutions purchase ARA-290 in bulk for large-scale studies?
Yes, research facilities and institutions can request bulk quantities and continuous supply contracts through the PX1 Research wholesale procurement team.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.